Reslizumab Sch 55700|cas:241473-69-8|西域试剂

Reslizumab Sch 55700,99.4%

产品编号：Bellancom-P9949| CAS NO：241473-69-8

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P9949		￥10000.00	杭州北京（现货）
Bellancom-P9949		￥18000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Reslizumab Sch 55700

产品介绍

Reslizumab (Sch 55700) 是靶向人白介素 5 (IL-5) 的人源化单克隆抗体，用于研究嗜酸性粒细胞性哮喘。Reslizumab 可有效阻断 IL-5 的功能。Reslizumab 对人 IL-5 具有高结合亲和力，在 Biacore 表面等离振子共振和动力学排斥分析中，K_D 值分别为 109 pM 和 4.3 pM。

生物活性

Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with K_D values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively.

体外研究

Reslizumab (Sch 55700) (0-10 nM, 48 h) inhibits IL-5-dependent cell proliferation, with an IC₅₀ value of approximately 91.1pM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	Human erythroleukemic TF-1 cell line
Concentration:	0-10 nM
Incubation Time:	48 h
Result:	Showed antiproliferative activity with an IC₅₀ of 91.1 pM.

体内研究
(In Vivo)

Reslizumab (Sch 55700) (0-10 mg/kg; i.p. or i.m.) inhibits pulmonary eosinophilia in a dose-dependent manner in allergic mice.
Reslizumab (0.03-30 mg/kg; i.p.) inhibits both the pulmonary eosinophilia and airway hyperresponsiveness, and at 30 mg/kg, i.p. inhibits allergic, but not histamine-induced bronchoconstriction in allergic guinea pigs.
Reslizumab (0.1-1 mg/kg; i.p.) blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs.
Reslizumab (0.3 mg/kg; i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months in allergic cynomolgus monkeys.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male B6D2F1/J mice weighing 20−25 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 µg of ovalbumin (OVA) adsorbed to 2 mg of aluminum hydroxide gel in saline vehicle)
Dosage:	0−10 mg/kg
Administration:	Intraperitoneal or intramuscular injection (For studies involving i.p. dose-response and i.m. evaluation, the antibody was given 2 h before OVA challenge. For experiments involving duration of activity, the antibody was given at times of 2 h or 4, 6, 8 or 12 weeks before antigen challenge.)
Result:	Inhibited the influx of eosinophils into the lungs for a long time (up to 8 weeks after administration of 10 mg/kg and for up to 4 weeks after administration of 2 mg/kg. Demonstrated an anti-inflammatory activity that was additive to that of oral Prednisolone (HY-17463).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male B6D2F1/J mice weighing 20−25 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 µg of ovalbumin (OVA) adsorbed to 2 mg of aluminum hydroxide gel in saline vehicle)
Dosage:	0−10 mg/kg
Administration:	Intraperitoneal or intramuscular injection (For studies involving i.p. dose-response and i.m. evaluation, the antibody was given 2 h before OVA challenge. For experiments involving duration of activity, the antibody was given at times of 2 h or 4, 6, 8 or 12 weeks before antigen challenge.)
Result:	Inhibited the influx of eosinophils into the lungs for a long time (up to 8 weeks after administration of 10 mg/kg and for up to 4 weeks after administration of 2 mg/kg. Demonstrated an anti-inflammatory activity that was additive to that of oral Prednisolone (HY-17463).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male B6D2F1/J mice weighing 20−25 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 µg of ovalbumin (OVA) adsorbed to 2 mg of aluminum hydroxide gel in saline vehicle)
Dosage:	0−10 mg/kg
Administration:	Intraperitoneal or intramuscular injection (For studies involving i.p. dose-response and i.m. evaluation, the antibody was given 2 h before OVA challenge. For experiments involving duration of activity, the antibody was given at times of 2 h or 4, 6, 8 or 12 weeks before antigen challenge.)
Result:	Inhibited the influx of eosinophils into the lungs for a long time (up to 8 weeks after administration of 10 mg/kg and for up to 4 weeks after administration of 2 mg/kg. Demonstrated an anti-inflammatory activity that was additive to that of oral Prednisolone (HY-17463).